A fine-tuned β-catenin regulation during proliferation of corneal endothelial cells revealed using proteomics analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
03
03
2020
accepted:
22
07
2020
entrez:
16
8
2020
pubmed:
17
8
2020
medline:
10
2
2021
Statut:
epublish
Résumé
Corneal endothelial (CE) dysfunction is the main indication for corneal transplantation, an invasive procedure with several limitations. Developing novel strategies to re-activate CE regenerative capacity is, therefore, of fundamental importance. This goal has proved to be challenging as corneal endothelial cells (CEnC) are blocked in the G0/G1 phase of the cell cycle in vivo and, albeit retaining proliferative capacity in vitro, this is further hindered by endothelial-to-mesenchymal transition. Herein we investigated the mechanisms regulating CEnC proliferation in vitro. Comparing the proteome of non-proliferating (in vivo-G0/G1) and proliferating (in vitro-G2/M) rabbit CEnC (rCEnC), 77 proteins, out of 3,328 identified, were differentially expressed in the two groups (p < 0.005). Literature and Gene Ontology analysis revealed β-catenin and transforming growth factor (TGF-β) pathways to be correlated with the identified proteins. Treatment of rCEnC with a β-catenin activator and inhibitor showed that β-catenin activation was necessary during rCEnC proliferation, but not sufficient for its induction. Furthermore, both pro-proliferative activity of basic fibroblast growth factor and anti-proliferative effects of TGF-β were regulated through β-catenin. Overall, these results provide novel insights into the molecular basis underlying the proliferation process that CEnC re-activate in vitro, consolidating the role of β-catenin and TGF-β.
Identifiants
pubmed: 32796906
doi: 10.1038/s41598-020-70800-w
pii: 10.1038/s41598-020-70800-w
pmc: PMC7427785
doi:
Substances chimiques
Transforming Growth Factor beta
0
beta Catenin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13841Références
Biol Open. 2014 Sep 12;3(10):937-46
pubmed: 25217618
Sci Rep. 2016 Aug 16;6:31162
pubmed: 27526633
J Biol Chem. 2007 Mar 2;282(9):6444-54
pubmed: 17209046
Hum Mol Genet. 2013 Apr 1;22(7):1271-9
pubmed: 23257286
Biochim Biophys Acta. 2009 Jul;1788(7):1458-65
pubmed: 19376086
Invest Ophthalmol Vis Sci. 1996 Mar;37(4):645-55
pubmed: 8595965
Cancer Biol Ther. 2006 Sep;5(9):1059-64
pubmed: 16940750
Exp Eye Res. 2012 Feb;95(1):35-9
pubmed: 21855543
PLoS One. 2013 May 10;8(5):e64231
pubmed: 23675531
Exp Cell Res. 2009 Jul 1;315(11):1819-31
pubmed: 19361498
Development. 2014 Nov;141(22):4243-53
pubmed: 25371361
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):189-96
pubmed: 18172092
Nat Rev Drug Discov. 2004 Jun;3(6):479-87
pubmed: 15173837
J Biol Chem. 2009 Oct 2;284(40):27701-11
pubmed: 19635798
Mol Vis. 2005 May 06;11:328-34
pubmed: 15889017
J Cell Sci. 2013 Mar 15;126(Pt 6):1392-405
pubmed: 23418351
Int J Mol Med. 2017 Feb;39(2):479-483
pubmed: 28075456
Food Funct. 2014 Oct;5(10):2564-73
pubmed: 25138740
Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3142-9
pubmed: 11726615
Nat Cell Biol. 2018 Apr;20(4):479-491
pubmed: 29593326
Nat Commun. 2019 Mar 20;10(1):1284
pubmed: 30894546
Exp Eye Res. 2005 Dec;81(6):629-38
pubmed: 16054624
Invest Ophthalmol Vis Sci. 2014 May 15;55(6):3700-8
pubmed: 24833739
Invest Ophthalmol Vis Sci. 1989 Jul;30(7):1548-59
pubmed: 2787301
J Mol Med (Berl). 2008 May;86(5):507-22
pubmed: 18322670
Oncotarget. 2017 May 19;8(42):73219-73239
pubmed: 29069865
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2513-9
pubmed: 10509644
Traffic. 2011 Jan;12(1):19-27
pubmed: 20950345
J Cell Sci. 2012 Aug 1;125(Pt 15):3636-48
pubmed: 22505615
Exp Eye Res. 2016 Nov;152:57-70
pubmed: 27639516
Sci Rep. 2018 Mar 13;8(1):4438
pubmed: 29535350
Nat Cell Biol. 2010 Jan;12(1):31-40; sup pp 1-9
pubmed: 20010817
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4803-9
pubmed: 17065491
Exp Eye Res. 2019 Feb;179:75-92
pubmed: 30365943
Stem Cells Transl Med. 2016 Feb;5(2):258-64
pubmed: 26702128
Invest Ophthalmol Vis Sci. 2004 Jun;45(6):2033-8
pubmed: 15161872
Stem Cells Dev. 2013 Mar 1;22(5):828-39
pubmed: 22974347
Exp Cell Res. 2019 May 15;378(2):139-148
pubmed: 30826396
Gene. 2008 Apr 15;412(1-2):84-94
pubmed: 18313863
J Biol Chem. 2010 Mar 12;285(11):8196-206
pubmed: 20061390
Biochem Biophys Res Commun. 2005 Mar 4;328(1):227-34
pubmed: 15670774
Exp Eye Res. 1992 Mar;54(3):447-54
pubmed: 1521572
Stem Cells. 2013 Jul;31(7):1396-407
pubmed: 23553870
Front Med (Lausanne). 2015 Sep 03;2:59
pubmed: 26389119
Invest Ophthalmol Vis Sci. 2011 Oct 17;52(11):8216-23
pubmed: 21948550
Acta Ophthalmol Scand. 2003 Oct;81(5):517-25
pubmed: 14510802
Exp Mol Med. 2019 May 23;51(5):1-16
pubmed: 31123246
Invest Ophthalmol Vis Sci. 2015 Feb 19;56(2):1228-37
pubmed: 25698769
J Biol Chem. 2015 Oct 30;290(44):26752-64
pubmed: 26370090
Cell. 2005 Dec 2;123(5):903-15
pubmed: 16325583
Surv Ophthalmol. 2018 Mar - Apr;63(2):149-165
pubmed: 28782549
Semin Cancer Biol. 2012 Oct;22(5-6):379-84
pubmed: 22554794
N Engl J Med. 2018 Mar 15;378(11):995-1003
pubmed: 29539291
Cell Oncol (Dordr). 2017 Apr;40(2):133-144
pubmed: 28039608
Exp Cell Res. 1995 Sep;220(1):36-46
pubmed: 7664841
Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2326-34
pubmed: 8843917
Exp Cell Res. 2006 Nov 1;312(18):3631-40
pubmed: 16963022
Sci Rep. 2016 Jul 06;6:29047
pubmed: 27381832
Development. 2009 Jan;136(2):241-51
pubmed: 19088090
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8281-8291
pubmed: 31966679
Cancer Invest. 2009 Jul;27(6):604-12
pubmed: 19440933
J Exp Clin Cancer Res. 2018 Jan 31;37(1):17
pubmed: 29386044
Exp Eye Res. 2012 Feb;95(1):2-7
pubmed: 21693119
J Biol Chem. 2018 Mar 9;293(10):3758-3769
pubmed: 29363574
Curr Eye Res. 1990 Oct;9(10):963-9
pubmed: 2276273
Invest Ophthalmol Vis Sci. 1977 Jul;16(7):597-613
pubmed: 873721
N Engl J Med. 2010 Jul 8;363(2):147-55
pubmed: 20573916
Stem Cell Reports. 2018 Jun 5;10(6):1851-1866
pubmed: 29706502
Ophthalmology. 1982 Jun;89(6):531-90
pubmed: 7122038
Oncogene. 2018 Feb 22;37(8):1049-1061
pubmed: 29084211
Cell Discov. 2017 Jan 31;3:17003
pubmed: 28417011
Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2152-9
pubmed: 12091410
Exp Eye Res. 2006 Dec;83(6):1309-16
pubmed: 16769055
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
J Interferon Cytokine Res. 1999 Apr;19(4):327-34
pubmed: 10334383
J Biomed Sci. 2013 Jun 25;20:41
pubmed: 23800047
Theranostics. 2018 Nov 10;8(21):5801-5813
pubmed: 30613263
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2930-5
pubmed: 10967047
Nat Commun. 2016 Oct 07;7:13101
pubmed: 27713415
Tissue Eng Part A. 2018 Apr;24(7-8):607-615
pubmed: 28726551
J Biol Chem. 2017 Jul 28;292(30):12503-12515
pubmed: 28559284
Elife. 2016 Jul 25;5:
pubmed: 27458801
J Cell Biol. 2001 Sep 17;154(6):1185-96
pubmed: 11564756
Cancer Res. 2006 May 1;66(9):4553-7
pubmed: 16651403
Development. 1993 May;118(1):117-26
pubmed: 7690700
EMBO J. 2004 Oct 13;23(20):4018-28
pubmed: 15385967
Mol Carcinog. 2016 May;55(5):743-56
pubmed: 25968914
Oncogene. 2005 Aug 29;24(37):5764-74
pubmed: 16123809